113.63
price up icon0.71%   0.60
 
loading
Precedente Chiudi:
$113.03
Aprire:
$112.95
Volume 24 ore:
1.15M
Relative Volume:
0.15
Capitalizzazione di mercato:
$141.41B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
23.92
EPS:
4.75
Flusso di cassa netto:
$9.84B
1 W Prestazione:
+3.32%
1M Prestazione:
+2.85%
6M Prestazione:
+19.08%
1 anno Prestazione:
+46.44%
Intervallo 1D:
Value
$112.30
$114.15
Intervallo di 1 settimana:
Value
$112.30
$117.60
Portata 52W:
Value
$72.43
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
113.68 144.54B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
772.41 729.58B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.06 405.32B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.88 336.11B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.58 227.85B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
80.28 212.71B 63.92B 17.43B 17.04B 6.87

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-25 Aggiornamento Needham Hold → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
07:08 AM

Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com

07:08 AM
pulisher
Jul 28, 2025

Why Gilead Sciences Stock Slipped Today - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits

Jul 28, 2025
pulisher
Jul 28, 2025

Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

TD Cowen Remains Bullish on Gilead Sciences (GILD) - Yahoo Finance

Jul 28, 2025
pulisher
Jul 27, 2025

What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st

Jul 27, 2025
pulisher
Jul 26, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences Stock Just Popped - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead upgraded to Buy at Needham on new HIV drug - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener

Jul 25, 2025
pulisher
Jul 25, 2025

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org

Jul 25, 2025
pulisher
Jul 25, 2025

Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire

Jul 24, 2025
pulisher
Jul 23, 2025

Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)

Jul 23, 2025
pulisher
Jul 23, 2025

AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE

Jul 23, 2025
pulisher
Jul 23, 2025

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter

Jul 23, 2025
pulisher
Jul 23, 2025

Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Gilead Sciences Inc Azioni (GILD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mercier Johanna
Chief Commercial Officer
Jul 15 '25
Sale
111.03
3,000
333,090
117,168
Dickinson Andrew D
Chief Financial Officer
Jul 15 '25
Sale
111.03
2,500
277,575
162,610
drug_manufacturers_general PFE
$24.14
price down icon 0.73%
drug_manufacturers_general SNY
$49.65
price up icon 0.30%
$302.90
price up icon 0.54%
drug_manufacturers_general NVO
$54.80
price down icon 20.57%
drug_manufacturers_general MRK
$80.28
price down icon 4.59%
Capitalizzazione:     |  Volume (24 ore):